A detailed history of Parkman Healthcare Partners LLC transactions in Axogen, Inc. stock. As of the latest transaction made, Parkman Healthcare Partners LLC holds 412,888 shares of AXGN stock, worth $6.65 Million. This represents 0.82% of its overall portfolio holdings.

Number of Shares
412,888
Holding current value
$6.65 Million
% of portfolio
0.82%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.52 - $14.69 $3.1 Million - $6.07 Million
412,888 New
412,888 $5.79 Million
Q2 2023

Aug 11, 2023

BUY
$8.5 - $10.38 $315,137 - $384,838
37,075 Added 16.57%
260,858 $2.38 Million
Q1 2023

May 12, 2023

BUY
$7.53 - $10.95 $253,971 - $369,321
33,728 Added 17.75%
223,783 $2.11 Million
Q4 2022

Feb 13, 2023

SELL
$9.44 - $13.09 $93,880 - $130,180
-9,945 Reduced 4.97%
190,055 $1.9 Million
Q3 2022

Nov 14, 2022

BUY
$8.14 - $12.25 $93,658 - $140,948
11,506 Added 6.1%
200,000 $2.38 Million
Q2 2022

Aug 12, 2022

BUY
$6.99 - $10.0 $416,233 - $595,470
59,547 Added 46.18%
188,494 $1.54 Million
Q1 2022

May 13, 2022

SELL
$7.26 - $10.7 $563,746 - $830,865
-77,651 Reduced 37.59%
128,947 $1.02 Million
Q4 2021

Feb 11, 2022

BUY
$8.8 - $16.0 $58,062 - $105,568
6,598 Added 3.3%
206,598 $1.94 Million
Q3 2021

Nov 12, 2021

SELL
$15.23 - $21.72 $573,439 - $817,801
-37,652 Reduced 15.84%
200,000 $3.16 Million
Q2 2021

Aug 13, 2021

BUY
$17.8 - $23.5 $463,743 - $612,245
26,053 Added 12.31%
237,652 $5.14 Million
Q1 2021

May 14, 2021

SELL
$17.18 - $22.6 $324,873 - $427,366
-18,910 Reduced 8.2%
211,599 $4.29 Million
Q4 2020

Feb 12, 2021

BUY
$11.5 - $17.96 $1.21 Million - $1.89 Million
105,509 Added 84.41%
230,509 $4.13 Million
Q3 2020

Nov 13, 2020

BUY
$10.62 - $13.12 $1.33 Million - $1.64 Million
125,000 New
125,000 $1.45 Million

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $681M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Parkman Healthcare Partners LLC Portfolio

Follow Parkman Healthcare Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.